Hyperuricemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hyperuricemia – Drugs In Development, 2024 report and make more profitable business decisions.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include swollen, tender, and red joints; fever, chills, fatigue, and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history, and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.
The Hyperuricemia drugs in development market research report provide comprehensive information on the therapeutics under development for Hyperuricemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hyperuricemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 34 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hyperuricemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hyperuricemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hyperuricemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAmendment Biomedical (Hangzhou) Research Institute Co Ltd
Arthrosi Therapeutics Inc
AstraZeneca Plc
Baylor College of Medicine
China Medical University
Evopoint Bioscience Co Ltd
Fochon Pharmaceutical Ltd
Fuji Yakuhin Co Ltd
Guangdong East Sunshine Pharmaceutical Co Ltd
Hangzhou Grand Biologic Pharmaceutical Inc
Hinova Pharmaceuticals Co Ltd
Innovent Biologics Inc
InventisBio Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
Shanghai Institute of Biological Products Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shanton Pharma Co Ltd
Shenyang Pharmaceutical University
Stealth Biologics LLC
Teijin Pharma Ltd
The United Laboratories International Holdings Ltd
Tianjin Institute of Pharmaceutical Research
Tonghua Dongbao Pharmaceutical Co Ltd
Waterstone Pharmaceuticals (Wuhan) Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hyperuricemia reports